Advanced Risk Assessment in Patients with Kidney and Inflammatory Diseases

[1]  J. Heinz,et al.  Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  G. Bakris,et al.  Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? , 2009, Current opinion in nephrology and hypertension.

[3]  M. Chonchol,et al.  Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). , 2009, Atherosclerosis.

[4]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[5]  G. Bakris,et al.  The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. , 2009, Kidney international.

[6]  G. Bakris,et al.  The Message for World Kidney Day 2009 , 2009, American Journal of Nephrology.

[7]  K. Tuttle,et al.  Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury? , 2008, Current opinion in nephrology and hypertension.

[8]  D. Levy,et al.  Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  G. Watts,et al.  Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. , 2008, Atherosclerosis.

[10]  F. Dekker,et al.  Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients--no additional power for mortality prediction with high-sensitivity CRP. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  P. Tsao,et al.  Asymmetrical Dimethylarginine in Renal Disease: Limits of Variation or Variation Limits? , 2007, American Journal of Nephrology.

[12]  M. Jardine,et al.  Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. , 2007, Journal of the American Society of Nephrology : JASN.

[13]  J. Bragg-Gresham,et al.  Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  Keith C. Norris,et al.  Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  D. Levy,et al.  Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. , 2006, Archives of internal medicine.

[16]  W. Daniel,et al.  Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. , 2006, American heart journal.

[17]  G. Beck,et al.  Relationship Between Homocysteine and Mortality in Chronic Kidney Disease , 2006, Circulation.

[18]  K. Borch-Johnsen,et al.  Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. , 2006, Diabetes care.

[19]  M. Landray,et al.  The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  B. Astor,et al.  Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. , 2006, American heart journal.

[21]  A. Levin,et al.  Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? , 2005, Kidney international.

[22]  J. Cox,et al.  Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  P. Parfrey,et al.  The clinical epidemiology of cardiovascular disease in chronic kidney disease , 2005, Current opinion in nephrology and hypertension.

[24]  R. Schnabel,et al.  Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease: Results from the AtheroGene Study , 2005, Circulation research.

[25]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[26]  Florian Kronenberg,et al.  Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.

[27]  M. Landray,et al.  First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  C. Boos.  Cardiovascular protection with ace inhibitors--more HOPE for EUROPA? , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[29]  N. Levin,et al.  POOR NUTRITIONAL STATUS AND INFLAMMATION: C‐Reactive Protein and End‐Stage Renal Disease , 2004 .

[30]  Jordan J. Cohen,et al.  Atherosclerosis and uremic retention solutes. , 2004, Kidney international.

[31]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[32]  H. Bloomfield,et al.  Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. , 2004, Kidney international.

[33]  Arvind Shah,et al.  Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). , 2004, Diabetes care.

[34]  B. Astor,et al.  Evidence for increased cardiovascular disease risk in patients with chronic kidney disease , 2004, Current opinion in nephrology and hypertension.

[35]  A. Collins,et al.  Chronic kidney disease and cardiovascular disease in the Medicare population. , 2003, Kidney international. Supplement.

[36]  C. Herzog.  How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. , 2003, Journal of the American Society of Nephrology : JASN.

[37]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[38]  A. Jaffe,et al.  Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination , 2002, Annals of Internal Medicine.

[39]  M. Mcclellan,et al.  Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients , 2002, Annals of Internal Medicine.

[40]  M. Goolsby.  National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, Journal of the American Academy of Nurse Practitioners.

[41]  Jiang He,et al.  Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. , 2002, Journal of the American Society of Nephrology : JASN.

[42]  A. Zanchetti,et al.  Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. , 2001, Journal of the American Society of Nephrology : JASN.

[43]  W. Keane.  Proteinuria: its clinical importance and role in progressive renal disease. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[44]  E. Ritz,et al.  Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[45]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[46]  B. Kasiske,et al.  Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. , 1997, Kidney international. Supplement.

[47]  J. Himmelfarb,et al.  Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. , 1997, Journal of the American Society of Nephrology : JASN.

[48]  C. Zoccali,et al.  Novel cardiovascular risk factors in end-stage renal disease. , 2004, Journal of the American Society of Nephrology : JASN.

[49]  C. Pollock,et al.  Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[50]  Deeb N Salem,et al.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. , 2003, Journal of the American College of Cardiology.